Company overview
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing MLTX with another company.
| Daily close (USD) | $10.58 |
| Market capitalization (USD) | $900,428,727.3 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.1 |
No matching rows. Clear the filter to see all records.
Read MLTX's valuation metrics
Company size
MoonLake Immunotherapeutics Class A Ordinary Shares's recorded market capitalization is $900,428,727.3. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
MLTX's recorded price-to-book ratio is 2.1. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research MoonLake Immunotherapeutics Class A Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about MLTX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow MLTX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.